Mi-Ae Kim1, Kenji Izuhara2, Shoichiro Ohta3, Junya Ono4, Moon Kyung Yoon5, Ga Young Ban5, Hye-Soo Yoo5, Yoo Seob Shin5, Young-Min Ye5, Dong-Ho Nahm5, Hae-Sim Park6. 1. Department of Allergy and Clinical Immunology, CHA Bundang Medical Center, CHA University, Seongnam, Korea. 2. Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan. 3. Department of Laboratory Medicine, Saga Medical School, Saga, Japan. 4. Shino-Test Corporation, Kanagawa, Japan. 5. Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. 6. Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea; Department of Biomedical Science, Ajou University Graduate School, Suwon, Korea. Electronic address: hspark@ajou.ac.kr.
Abstract
BACKGROUND: Recent studies recommend periostin as a systemic biomarker of eosinophilic airway inflammation to predict responses to novel treatments that targets eosinophilic TH2-driven inflammation in asthmatic patients. OBJECTIVE: To investigate the clinical implications of serum periostin levels in patients with aspirin-exacerbated respiratory disease (AERD) based on its overlapping TH2-mediated pathogenesis with the eosinophilic asthma. METHODS: Serum periostin levels were measured by human periostin enzyme-linked immunosorbent assay (ELISA) in serum samples from 277 adults with asthma. Serum periostin levels were compared between patients with AERD and aspirin tolerant asthma (ATA) with other asthma phenotypes, such as severe or nonsevere asthma and eosinophilic or noneosinophilic asthma. The association of serum periostin levels with clinical parameters (including disease severity and comorbid condition) was analyzed. RESULTS: Serum periostin levels were significantly higher in patients with AERD vs ATA, patients with severe asthma vs nonsevere asthma, and patients with eosinophilic asthma vs noneosinophilic asthma (P=.005, P=.02, and P=.001, respectively). Multivariate regression analysis revealed serum periostin levels as a significant parameter to predict AERD phenotype (P=.006) together with severe asthma phenotype (P=.04). In addition, serum periostin levels correlated with blood eosinophil counts (Spearman ñ = 0.244, P<.001) and sputum eosinophil counts (Spearman ñ = 0.261, P < 0.001). Higher serum periostin levels were noted in comorbid AERD patients with more severe chronic rhinosinusitis (Lund-Mackay stages 3 and 4) than those with less severe chronic rhinosinusitis (Lund-Mackay stages 1 and 2) (P = .03). CONCLUSION: Serum periostin levels are significantly elevated in AERD patients and associated with AERD phenotype and disease severity.
BACKGROUND: Recent studies recommend periostin as a systemic biomarker of eosinophilic airway inflammation to predict responses to novel treatments that targets eosinophilic TH2-driven inflammation in asthmatic patients. OBJECTIVE: To investigate the clinical implications of serum periostin levels in patients with aspirin-exacerbated respiratory disease (AERD) based on its overlapping TH2-mediated pathogenesis with the eosinophilic asthma. METHODS: Serum periostin levels were measured by humanperiostin enzyme-linked immunosorbent assay (ELISA) in serum samples from 277 adults with asthma. Serum periostin levels were compared between patients with AERD and aspirintolerant asthma (ATA) with other asthma phenotypes, such as severe or nonsevere asthma and eosinophilic or noneosinophilic asthma. The association of serum periostin levels with clinical parameters (including disease severity and comorbid condition) was analyzed. RESULTS: Serum periostin levels were significantly higher in patients with AERD vs ATA, patients with severe asthma vs nonsevere asthma, and patients with eosinophilic asthma vs noneosinophilic asthma (P=.005, P=.02, and P=.001, respectively). Multivariate regression analysis revealed serum periostin levels as a significant parameter to predict AERD phenotype (P=.006) together with severe asthma phenotype (P=.04). In addition, serum periostin levels correlated with blood eosinophil counts (Spearman ñ = 0.244, P<.001) and sputum eosinophil counts (Spearman ñ = 0.261, P < 0.001). Higher serum periostin levels were noted in comorbid AERD patients with more severe chronic rhinosinusitis (Lund-Mackay stages 3 and 4) than those with less severe chronic rhinosinusitis (Lund-Mackay stages 1 and 2) (P = .03). CONCLUSION: Serum periostin levels are significantly elevated in AERD patients and associated with AERD phenotype and disease severity.
Authors: Kenji Izuhara; Simon J Conway; Bethany B Moore; Hisako Matsumoto; Cecile T J Holweg; John G Matthews; Joseph R Arron Journal: Am J Respir Crit Care Med Date: 2016-05-01 Impact factor: 21.405
Authors: Dae Woo Kim; Marianna Kulka; Ara Jo; Kyoung Mi Eun; Narcy Arizmendi; Brian P Tancowny; Seung-No Hong; Jung Pyo Lee; Hong Ryul Jin; Richard F Lockey; Dong-Kyu Kim; Seong H Cho Journal: J Allergy Clin Immunol Date: 2016-10-19 Impact factor: 10.793
Authors: Jodie L Simpson; Ian A Yang; John W Upham; Paul N Reynolds; Sandra Hodge; Alan L James; Christine Jenkins; Matthew J Peters; Guiquan Jia; Cecile T J Holweg; Peter G Gibson Journal: BMC Pulm Med Date: 2016-04-30 Impact factor: 3.317